<DOC>
	<DOC>NCT02807844</DOC>
	<brief_summary>The purpose of this study of MCS110 with PDR001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the combination of MCS110 with PDR001 in adult patients with solid tumors.</brief_summary>
	<brief_title>Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Signed informed consent prior to any procedures Patients with advanced melanoma, endometrial carcinoma, pancreatic or TNBC, with measurable or nonmeasurable disease who have progressed despite standard therapy or are intolerant of standard therapy, or for whom no standard therapy exists. Patient having out of range laboratory values defined as: Creatinine clearance &lt; 40 mL/min Total bilirubin &gt; 1.5 x ULN Absolute neutrophil count &lt; 1.0 x 109/L Hemoglobin (Hgb) &lt; 9 g/dL Impaired cardiac function or clinically significant cardiac disease Active autoimmune disease Malignant disease, other than that being treated in this study. Presence of â‰¥ CTCAE Grade 2 toxicity due to prior cancer therapy. Pregnant or lactating women Other protocoldefined inclusion/exclusion may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Triple negative breast cancer</keyword>
	<keyword>Pancreatic carcinoma</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Endometrial Carcinoma</keyword>
	<keyword>Immuno oncology</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>PDR001</keyword>
	<keyword>MCS110</keyword>
</DOC>